Comparative Pharmacology
Head-to-head clinical analysis: EVZIO AUTOINJECTOR versus NALMEFENE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVZIO AUTOINJECTOR versus NALMEFENE HYDROCHLORIDE.
EVZIO (AUTOINJECTOR) vs NALMEFENE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.
Nalmefene is an opioid receptor antagonist with high affinity for mu, kappa, and delta receptors, and partial agonist activity at kappa receptors.
Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.
18 mcg intranasally once, repeated after 2-3 minutes if needed; maximum 2 doses (36 mcg) per episode. Alternatively, 0.5 mg subcutaneously or intramuscularly once, repeated after 2-3 minutes if needed; maximum 1.5 mg per episode.
None Documented
None Documented
Terminal elimination half-life of naloxone is approximately 1–2 hours in adults. The short half-life results in a duration of action that may be shorter than that of the opioid (e.g., fentanyl, methadone), necessitating repeated doses or continuous infusion. In neonates, half-life is prolonged (3–4 hours).
Terminal elimination half-life: ~10.8 hours (range 8–13 hours); clinically supports twice-daily dosing or use in alcohol use disorder
Naloxone is primarily metabolized in the liver via glucuronidation, with minor contributions from N-dealkylation. The metabolites (naloxone-3-glucuronide) and parent drug are excreted renally. Approximately 50% of a dose is excreted in urine as naloxone-3-glucuronide, 25% as unchanged naloxone (after IV), and <5% in feces. Biliary excretion is minimal (<1%).
Primarily renal (approximately 50% unchanged drug); biliary/fecal excretion accounts for ~20%
Category C
Category C
Opioid Antagonist
Opioid Antagonist